# Phio Pharmaceuticals Corp.: financial statements, quarterly

PHIO · Nasdaq · CIK 1533040 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/phio.md) · [Financials](/companies/phio/financials.md) · [Filings](/companies/phio/filings.md) · [Insiders](/companies/phio/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/phio/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [1,808](/filings/0001683168-24-008120.md) | [1,007 d](/filings/0001683168-25-002134.md) | [1,148](/filings/0001683168-25-003719.md) | [866](/filings/0001683168-25-006174.md) | [644](/filings/0001437749-25-034857.md) | [985 d](/filings/0001437749-26-007078.md) | [886](/filings/0001437749-26-015604.md) | [1,074](/filings/0001437749-26-026271.md) | [1,181](/filings/0001437749-25-034857.md) | [1,477 d](/filings/0001437749-26-007078.md) | [2,793](/filings/0001437749-26-015604.md) | [3,082](/filings/0001437749-26-026271.md) |
| Operating income | $k | [(2,776)](/filings/0001683168-24-008120.md) | [(1,899) d](/filings/0001683168-25-002134.md) | [(2,209)](/filings/0001683168-25-003719.md) | [(1,914)](/filings/0001683168-25-006174.md) | [(1,590)](/filings/0001437749-25-034857.md) | [(1,674) d](/filings/0001437749-26-007078.md) | [(1,872)](/filings/0001437749-26-015604.md) | [(2,309)](/filings/0001437749-26-026271.md) | [(2,505)](/filings/0001437749-25-034857.md) | [(2,534) d](/filings/0001437749-26-007078.md) | [(4,167)](/filings/0001437749-26-015604.md) | [(4,268)](/filings/0001437749-26-026271.md) |
| Interest expense | $k | not reported | not reported | [(53.0)](/filings/0001683168-25-003719.md) | not reported | not reported | not reported | [(125)](/filings/0001683168-25-003719.md) | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(2,780)](/filings/0001683168-24-008120.md) | [(1,895) d](/filings/0001683168-25-002134.md) | [(2,154)](/filings/0001437749-25-034857.md) | [(1,846)](/filings/0001437749-25-034857.md) | [(1,524)](/filings/0001437749-25-034857.md) | [(1,626) d](/filings/0001437749-26-007078.md) | [(1,769)](/filings/0001437749-26-026271.md) | [(2,166)](/filings/0001437749-26-026271.md) | [(2,392)](/filings/0001437749-25-034857.md) | [(2,371) d](/filings/0001437749-26-007078.md) | [(4,003)](/filings/0001437749-26-026271.md) | [(4,138)](/filings/0001437749-26-026271.md) |
| Diluted EPS | $ per share | [(10.25)](/filings/0001683168-24-008120.md) | not reported | [(0.47)](/filings/0001683168-25-003719.md) | [(3.62)](/filings/0001683168-25-006174.md) | [(1.54)](/filings/0001683168-24-008120.md) | not reported | [(0.41)](/filings/0001683168-25-003719.md) | [(0.45)](/filings/0001683168-25-006174.md) | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(10.25)](/filings/0001683168-24-008120.md) | not reported | [(0.47)](/filings/0001683168-25-003719.md) | [(3.62)](/filings/0001683168-25-006174.md) | [(1.54)](/filings/0001437749-25-034857.md) | not reported | [(0.41)](/filings/0001437749-26-015604.md) | [(0.45)](/filings/0001437749-26-026271.md) | [(0.44)](/filings/0001437749-25-034857.md) | not reported | [(0.34)](/filings/0001437749-26-015604.md) | [(0.36)](/filings/0001437749-26-026271.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [8.4](/filings/0001683168-24-008120.md) | [8.5](/filings/0001683168-25-002134.md) | [6.5](/filings/0001683168-24-003175.md) | [4.7](/filings/0001683168-24-005706.md) | [5.4](/filings/0001683168-24-008120.md) | [5.4](/filings/0001437749-26-007078.md) | [13.3](/filings/0001683168-25-003719.md) | [10.8](/filings/0001683168-25-006174.md) | [10.7](/filings/0001437749-25-034857.md) | [21.0](/filings/0001437749-26-026271.md) | [17.0](/filings/0001437749-26-015604.md) | [13.0](/filings/0001437749-26-026271.md) |
| Current assets | $m | [9.3](/filings/0001683168-23-007809.md) | [9.3](/filings/0001683168-25-002134.md) | [6.8](/filings/0001683168-24-003175.md) | [5.3](/filings/0001683168-24-005706.md) | [5.9](/filings/0001683168-24-008120.md) | [5.7](/filings/0001437749-26-007078.md) | [13.4](/filings/0001683168-25-003719.md) | [11.3](/filings/0001683168-25-006174.md) | [11.5](/filings/0001437749-25-034857.md) | [21.5](/filings/0001437749-26-026271.md) | [17.4](/filings/0001437749-26-015604.md) | [14.3](/filings/0001437749-26-026271.md) |
| Total assets | $m | [9.5](/filings/0001683168-23-007809.md) | [9.4](/filings/0001683168-25-002134.md) | [6.9](/filings/0001683168-24-003175.md) | [5.3](/filings/0001683168-24-005706.md) | [5.9](/filings/0001683168-24-008120.md) | [5.7](/filings/0001437749-26-007078.md) | [13.4](/filings/0001683168-25-003719.md) | [11.3](/filings/0001683168-25-006174.md) | [11.5](/filings/0001437749-25-034857.md) | [21.5](/filings/0001437749-26-026271.md) | [17.4](/filings/0001437749-26-015604.md) | [14.3](/filings/0001437749-26-026271.md) |
| Current liabilities | $m | [2.3](/filings/0001683168-23-007809.md) | [1.6](/filings/0001683168-25-002134.md) | [1.2](/filings/0001683168-24-003175.md) | [1.5](/filings/0001683168-24-005706.md) | [0.9](/filings/0001683168-24-008120.md) | [1.0](/filings/0001683168-25-006174.md) | [1.3](/filings/0001683168-25-003719.md) | [1.2](/filings/0001683168-25-006174.md) | not reported | not reported | not reported | not reported |
| Total liabilities | $m | [2.3](/filings/0001683168-23-007809.md) | [1.6](/filings/0001683168-25-002134.md) | not reported | not reported | not reported | [1.0](/filings/0001437749-26-007078.md) | [1.3](/filings/0001683168-25-003719.md) | [1.2](/filings/0001683168-25-006174.md) | [1.7](/filings/0001437749-25-034857.md) | [1.3](/filings/0001437749-26-026271.md) | [1.0](/filings/0001437749-26-015604.md) | [1.7](/filings/0001437749-26-026271.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [7.2](/filings/0001683168-24-008120.md) | [7.7](/filings/0001437749-26-007078.md) | [5.6](/filings/0001437749-25-034857.md) | [3.8](/filings/0001437749-25-034857.md) | [4.9](/filings/0001437749-25-034857.md) | [4.7](/filings/0001437749-26-026271.md) | [12.2](/filings/0001437749-26-026271.md) | [10.1](/filings/0001437749-26-026271.md) | [9.8](/filings/0001437749-25-034857.md) | [20.1](/filings/0001437749-26-026271.md) | [16.5](/filings/0001437749-26-026271.md) | [12.6](/filings/0001437749-26-026271.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,900) d](/filings/0001683168-24-008120.md) | [(2,370) d](/filings/0001683168-25-002134.md) | [(2,011)](/filings/0001683168-25-003719.md) | [(1,777) d](/filings/0001683168-25-006174.md) | [(1,953) d](/filings/0001437749-25-034857.md) | [(1,371) d](/filings/0001437749-26-007078.md) | [(1,275)](/filings/0001437749-26-015604.md) | [(2,540) d](/filings/0001437749-26-026271.md) | [(2,085) d](/filings/0001437749-25-034857.md) | [(2,079) d](/filings/0001437749-26-007078.md) | [(4,003)](/filings/0001437749-26-015604.md) | [(4,035) d](/filings/0001437749-26-026271.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001683168-24-008120.md) | [0.0 d](/filings/0001683168-25-002134.md) | [0.0](/filings/0001683168-25-003719.md) | [0.0 d](/filings/0001683168-25-006174.md) | [0.0 d](/filings/0001437749-25-034857.md) | [1.0 d](/filings/0001437749-26-007078.md) | [2.0](/filings/0001437749-26-015604.md) | [3.0 d](/filings/0001437749-26-026271.md) | [7.0 d](/filings/0001437749-25-034857.md) | [0.0 d](/filings/0001437749-26-007078.md) | [0.0](/filings/0001437749-26-015604.md) | [0.0 d](/filings/0001437749-26-026271.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [13.5](/filings/0001683168-22-007528.md) | [1.1](/filings/0001683168-23-003213.md) | [1,138](/filings/0001683168-23-005514.md) | [1.1](/filings/0001683168-23-007809.md) | [1.1](/filings/0001683168-24-003175.md) | [0.2](/filings/0001683168-24-005706.md) | [0.3](/filings/0001683168-24-008120.md) | [4.6](/filings/0001683168-25-003719.md) | [0.5](/filings/0001683168-25-006174.md) | [1.0](/filings/0001683168-24-008120.md) | [4.3](/filings/0001683168-25-003719.md) | [4.8](/filings/0001683168-25-006174.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 11,617,250 at 2026-08-04, from the cover of the [10-Q filed 2026-08-06](/filings/0001437749-26-026271.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.